Request based on partial clinical trial findings suggesting the drug reduces symptoms in mild or moderate COVID-19
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19.
The request to the U.S. Food and Drug Administration is based on partial clinical trial findings suggesting the drug reduced symptoms, the amount of virus, hospitalizations, and emergency department visits for patients with mild or moderate COVID-19, the Associated Press reported.
The results were released Wednesday in a news release, and they have not been published or reviewed by independent researchers.
The FDA granted emergency approval for the antiviral drug remdesivir, but it is not clear if there is enough evidence for Lilly’s antibody therapy to be approved, the AP reported.
Copyright © 2020 HealthDay. All rights reserved.